Compare Illumina, Inc. (ILMN) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Liberty Global Ltd Class C — how do they compare? Illumina, Inc. trades at $191.6 (market cap $27.94B), while Liberty Global Ltd Class C trades at $10 (market cap $3.47B). The key difference: Illumina, Inc. is far larger — about 8.1× Liberty Global Ltd Class C's market cap, and Illumina, Inc. is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| ILMN | LBTYK | |
|---|---|---|
Market Cap | $27.94B | $3.47B |
Sector | Health | Technology |
52-Week High | $194.33 | $12.67 |
52-Week Low | $91.00 | $10.00 |
Enterprise Value | $29.33B | $10.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
LBTYK trades at $9.995, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion for 2025, though revenue grew to $4.88 billion. Recent news highlights strategic moves, including the planned 2027 Amsterdam listing of Ziggo Group. Analyst consensus is strongly positive, with 69% recommending Buy.
The outlook hinges on execution of the Ziggo Group spin-off, a potential value catalyst. However, persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. The stock offers a deep value opportunity if management delivers on restructuring, but operational turnaround is critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
